Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.
Tumour necrosis factor-alpha inhibitors including infliximab are often used to treat a number of recalcitrant medical conditions. These agents are increasingly associated with infections, particularly mycobacterial infections. We report sporotrichoid spread of Mycobacterium marinum in a 37-year-old woman with Crohn's disease, who had been receiving infliximab infusions for 2 years. An infection had spread up the right leg, after she had been swimming on holiday in the Canary Islands. M. marinum was cultured from the lesions and also identified by PCR on formalin-fixed tissue. To our knowledge, this is the first report of M. marinum occurring in a patient receiving infliximab.
Fallon
J C
JC
Department of Dermatology, Beaumont Hospital, Dublin, Ireland. fallonjason@hotmail.com
Patchett
S
S
Gulmann
C
C
Murphy
G M
GM
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005533:Foot Dermatoses / Q000139:chemically induced / Q000175:diagnosis / Q000382:microbiology; D006801:Humans; D000069285:Infliximab; D009165:Mycobacterium Infections, Nontuberculous / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D019910:Mycobacterium marinum / Q000302:isolation & purification; D017192:Skin Diseases, Bacterial / Q000139:chemically induced* / Q000175:diagnosis / Q000382:microbiology; D013551:Swimming Pools
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab